Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.

导出 OA

翻译打印收藏纠错

第一作者： Weelic,Chong

第一单位： Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.

作者： Weelic,Chong ^[1] ; Zhenchao,Zhang ^[1] ; Rui,Luo ^[1] ; Jian,Gu ^[2] ; Jianqing,Lin ^[3] ; Qiang,Wei ^[4] ; Bingshan,Li ^[4] ; Ronald,Myers ^[1] ; Grace,Lu-Yao ^[1] ; William Kevin,Kelly ^[1] ; Chun,Wang ^[5] ; Hushan,Yang ^[6]

作者单位： Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. ^[1] Department of Epidemiology, MD Anderson Cancer Center, Houston, TX, 77030, USA. ^[2] Department of Medicine, GW Cancer Center, George Washington University, Washington, DC, 20037, USA. ^[3] Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, 37235, USA. ^[4] Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. chun.wang@jefferson.edu. ^[5] Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. hushan.yang@jefferson.edu. ^[6]

关键词 Circulating tumor cell Metastatic castration-resistant prostate cancer Neutrophil-lymphocyte ratio Platelet-lymphocyte ratio Prognosis